Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis

Immune-related enterocolitis (irEC) is the most common serious complication from checkpoint inhibitors (CPIs). The current front-line treatment for irEC, high-dose corticosteroids (CS), have significant side effects and prolonged therapy may reduce CPI-anti-tumor activity. Early addition of TNF-α in...

Full description

Saved in:
Bibliographic Details
Published in:Journal for immunotherapy of cancer 2018-10, Vol.6 (1), p.103-103, Article 103
Main Authors: Johnson, Daniel H, Zobniw, Chrystia M, Trinh, Van A, Ma, Junsheng, Bassett, Jr, Roland L, Abdel-Wahab, Noha, Anderson, Jaime, Davis, Jennifer E, Joseph, Jocelyn, Uemura, Marc, Noman, Ali, Abu-Sbeih, Hamzah, Yee, Cassian, Amaria, Rodabe, Patel, Sapna, Tawbi, Hussein, Glitza, Isabella C, Davies, Michael A, Wong, Michael K, Woodman, Scott, Hwu, Wen-Jen, Hwu, Patrick, Wang, Yinghong, Diab, Adi
Format: Article
Language:English
Subjects:
Abdomen
Cancer
Cancer therapies
Care and treatment
Comparative analysis
Corticosteroid drugs
Diarrhea
Documentation
Endoscopy
Enterocolitis
Gastrointestinal system
Generalized linear models
Immune checkpoint inhibitors
Immune-related enterocolitis
Immunotherapy
Inflammatory bowel disease
Infliximab
Medical records
Melanoma
Monoclonal antibodies
Patients
Steroids
TNF inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune-related enterocolitis (irEC) is the most common serious complication from checkpoint inhibitors (CPIs). The current front-line treatment for irEC, high-dose corticosteroids (CS), have significant side effects and prolonged therapy may reduce CPI-anti-tumor activity. Early addition of TNF-α inhibitors such as infliximab (IFX) may expedite symptom resolution and shorten CS duration. Thus, we conducted the first retrospective study, to our knowledge, evaluating symptom resolution in patients with irEC treated with and without IFX. Data were collected from the medical records of patients diagnosed with irEC. The primary endpoint was time to symptom resolution for irEC for cases managed with IFX plus CS (IFX group) versus CS alone (CS group). Duration of CS, overall survival (OS), and time to treatment failure (TTF) were secondary endpoints. Among 75 patients with irEC, 52% received CS alone, and 48% received IFX. Despite higher grade colitis in the IFX group (grade 3/4: 86% vs. 34%; p 
ISSN:2051-1426
2051-1426
DOI:10.1186/s40425-018-0412-0